Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24.
Benzinga · 2天前
Zogenix: Market Reaction To Fintepla's Approval Offers A Gift To Investors
Seeking Alpha - Article · 3天前
Nasdaq's $1.2 trln biotech index draws Europe's COVID drug hunters
Reuters · 3天前
Pharmamar Announces That It Has Received Payment of $100M From Jazz Pharmaceuticals for the Approval of Zepzelcatm (Lurbinectedin) in the U.s.
PharmaMar (MSE:PHM) has today announced that it has received payment of $100 million from Jazz Pharmaceuticals (NASDAQ: JAZZ), corresponding to the first part of the regulatory milestones, for the approval of lurbinectedin in the U.S. for the treatment of pati
Benzinga · 4天前
3 Reasons Jazz Pharmaceuticals Is A Hot Buy Right Now
MotleyFool.com · 06/23 11:06
BofA Raises Jazz Pharma Estimates After Zepzelca Update
Benzinga · 06/18 19:19
BofA Raises Jazz Pharma Estimates After Zepzelca Update
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) provided encouraging updates on its commercial efforts in a recent conference call on the lung cancer drug Zepzelca, according to BofA Securities.
Benzinga · 06/18 18:20
B of A Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $167
B of A Securities maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $165 to $167.
Jazz Pharmaceuticals Public Limited Company是一家生物制药公司。该公司致力于开发和商业化解决未满足的医疗需求的产品。该公司拥有针对睡眠和血液学/肿瘤学领域的多元化产品与候选产品组合。该公司的主导市场产品包括治疗发作性嗜睡病患者猝倒和日间过度嗜睡（EDS）的Xyrem（羟丁酸钠口服溶液）、治疗急性淋巴细胞白血病（ALL）的Erwinaze和治疗重度肝静脉闭塞性疾病（VOD）的Defitelio（去纤苷）。该公司的其他候选产品包括治疗发作性嗜睡病中的EDS与阻塞性睡眠呼吸暂停（OSA）患者的EDS的JZP-110，以及治疗发作性嗜睡病中的EDS的JZP-386。